GeNeuro: financial information and business update for the second quarter 2021
Geneva, Switzerland, July 23, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2021 second quarter cash position and issued a business update. https://geneuro.ch/data/news/GeNeuro-PR-Q2-2021-EN-VF.pdf